Home > Back to Publisher > Report Information

Personalized Medicine Partnering Terms & Agreements

Current Partnering
April 1, 2011
951 Pages - SKU: WWV6482804

Abstract Table of Contents Search inside this report Related Reports

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1500 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2005. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a review of the leading companion diagnostic deals since 2005. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a review of the leading pharmacogenomic deals since 2005. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 6 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2005, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2005, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of pharmacogenomic partnering deals signed and announced since 2005, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine partnering and dealmaking since 2005.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine technologies and products.

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in personalized medicine dealmaking: 2.1. Introduction; 2.2. Personalized medicine partnering over the years; 2.3. Bigpharma personalized medicine dealmaking activity; 2.4. Bigpharma not active in personalized medicine; 2.5. Personalized medicine partnering by deal type; 2.6. Personalized medicine partnering by disease type; 2.7 Average deal terms for personalized medicine; 2.8 Average deal terms for companion diagnostics; 2.9 Average deal terms for pharmacogenomics
Chapter 3 - Leading biomarker deals: 3.1. Introduction; 3.2. Top biomarker deals by value; 3.3. Top biomarker deals involving bigpharma
Chapter 4 - Leading companion diagnostic deals: 4.1. Introduction; 4.2. Top companion diagnostic deals by value; 4.3. Top companion diagnostic deals involving bigpharma
Chapter 5 - Leading pharmacogenomic deals: 5.1. Introduction; 5.2. Top pharmacogenomics deals by value; 5.3. Top pharmacogenomic deals involving bigpharma
Chapter 6 - Bigpharma personalized medicine deals: 6.1. Introduction; 6.2. How to use bigpharma personalized medicine partnering deals; 6.3. Bigpharma personalized medicine partnering company profiles
Chapter 7 - Biomarker dealmaking directory: 7.1. Introduction; 7.2. Company A-Z; 7.3. By stage of development; 7.4. By deal type; 7.5. By therapy area
Chapter 8 - Companion diagnostic dealmaking directory: 8.1. Introduction; 8.2. Company A-Z; 8.3. By stage of development; 8.4. By deal type; 8.5. By therapy area
Chapter 9 - Pharmacogenomics dealmaking directory: 9.1. Introduction; 9.2. Company A-Z; 9.3. By stage of development; 9.4. By deal type; 9.5. By therapy area
Chapter 10 - Companion diagnostics partnering resource center: 10.1. Online companion diagnostics partnering; 10.2. Companion diagnostic partnering events; 10.3. Further reading on personalized medicine dealmaking
Appendices: Appendix 1 - Deal type definitions; Appendix 2 - Example companion diagnostic partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports
Table of figures: Figure 1: Personalized medicine partnering since 2005; Figure 2: Biomarker partnering since 2005; Figure 3: Companion diagnostic partnering since 2005; Figure 4: Pharmacogenomic partnering since 2005; Figure 5: Bigpharma - top 50 - personalized medicine deals 2005 to 2010; Figure 6: Bigpharma - top 50 - biomarker deals 2005 to 2010; Figure 7: Bigpharma - top 50 - companion diagnostic deals 2005 to 2010; Figure 8: Bigpharma - top 50 - pharmacogenomic deals 2005 to 2010; Figure 9: Inactive bigpharma in personalized medicine 2005-2010; Figure 10: Inactive bigpharma in biomarker 2005-2010; Figure 11: Inactive bigpharma in companion diagnostic 2005-2010; Figure 12: Inactive bigpharma in pharmacogenomic 2005-2010; Figure 13: Personalized medicine partnering by deal type since 2005; Figure 14: Biomarker partnering by deal type since 2005; Figure 15: Companion diagnositc partnering by deal type since 2005; Figure 16: Pharmacogenomics partnering by deal type since 2005; Figure 17: Personalized medicine partnering by disease type since 2005; Figure 18: Personalized medicine partnering by oncology target since 2005; Figure 19: Biomarker partnering by disease type since 2005; Figure 20: Biomarker partnering by oncology target since 2005; Figure 21: Companion diagnostic partnering by disease type since 2005; Figure 22: Companion diagnostic partnering by oncology target since 2005; Figure 23: Pharmacogenomics partnering by disease type since 2005; Figure 24: Pharmacogenomic partnering by oncology target since 2005; Figure 25: Biomarker deals with a headline value; Figure 26: Biomarker deal headline value distribution, US$million; Figure 27: Biomarker deal headline value distribution, US$million - detail; Figure 28: Biomarker deals with upfront payment values; Figure 29: Biomarker deal upfront payment distribution, US$million; Figure 30: Biomarker deals with milestone payments; Figure 31: Biomarker deal milestone payment distribution, US$million; Figure 32: Biomarker deals with royalty rates, %; Figure 33: Biomarker deal royalty rate distribution, %; Figure 34: Companion diagnostic deals with a headline value; Figure 35: Companion diagnostic deal headline value distribution, US$million; Figure 36: Companion diagnostic deal headline value distribution, US$million - detail; Figure 37: Companion diagnostic deals with upfront payment values; Figure 38: Companion diagnostic deal upfront payment distribution, US$million; Figure 39: Companion diagnostic deals with milestone payments; Figure 40: Companion diagnostic deal milestone payment distribution, US$million; Figure 41: Companion diagnostic deals with milestone payments; Figure 42: Pharmacogenomic deals with a headline value; Figure 43: Pharmacogenomic deal headline value distribution, US$million; Figure 44: Pharmacogenomic deals with upfront payment values; Figure 45: Pharmacogenomic deal upfront payment distribution, US$million; Figure 46: Pharmacogenomic deals with milestone payments; Figure 47: Pharmacogenomic deal milestone payment distribution, US$million; Figure 48: Top biomarker deals by value since 2005; Figure 49: Top biomarker deals signed by bigpharma value since 2005; Figure 50: Top companion diagnostic deals by value since 2005; Figure 51: Top companion diagnostic deals signed by bigpharma value since 2005; Figure 52: Top pharmacogenomic deals by value since 2005; Figure 53: Top pharmacogenomic deals signed by bigpharma value since 2005; Figure 54: Online partnering resources; Figure 55: Forthcoming partnering events; Figure 56: Deal type definitions; Figure 57: Companion diagnostic partnering agreement between Roche, Rules-Based Medicine, and Psynova Neurotech, December 2009

Personalized Medicine Partnering Terms & Agreements

Share this report

Other tasks

Research Assistance

Related Markets

Personalized Medicine Reports

Free Alert Me service